title: Management of Medication-Related Osteonecrosis of the Jaw.
abstract: Medication-related osteonecrosis of the jaw (MRONJ) primarily involves patients receiving intravenous bisphosphonates for treatment of skeletal-related malignancies, oral bisphosphonates, and denosumab. There is no consensus regarding the clinical management of MRONJ. Successful treatment may be that which results in a cure, with complete mucosal coverage and elimination of disease, or that which improves the quality of life without a cure (palliation). Helping patients to understand the chronicity and potential progression of the disease is essential to a satisfactory outcome. This review aims to share our treatment approach to patients with MRONJ. Treatment can be divided into medical and surgical therapies.
authors.affiliation: Division Maxillofacial Surgery, Oakland Medical Center, Kaiser Permanente, 3600 Broadway Kaiser, Oakland, CA 94611, USA.
authors.forename: William Bradford
authors.initials: WB
authors.lastname: Williams
authors.affiliation: Division Maxillofacial Surgery, Oakland Medical Center, Kaiser Permanente, 3600 Broadway Kaiser, Oakland, CA 94611, USA. Electronic address: Felice.O'Ryan@kp.org.
authors.forename: Felice
authors.initials: F
authors.lastname: O'Ryan
mesh_terms: D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000628:therapy*; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D000069448:Denosumab / Q000009:adverse effects*; D004164:Diphosphonates / Q000009:adverse effects*; D018450:Disease Progression; D006801:Humans
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000069448:Denosumab
keywords: BRONJ; Bisphosphonate; Denosumab; MRONJ; Maxillofacial surgery; Oral surgery